London · Delayed Price · Currency is GBP · Price in GBX Creo Medical Group Statistics
Total Valuation
AIM:CREO has a market cap or net worth of GBP 61.76 million. The enterprise value is 53.46 million.
| Market Cap | 61.76M |
| Enterprise Value | 53.46M |
Important Dates
The next estimated earnings date is Monday, June 22, 2026.
| Earnings Date | Jun 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM:CREO has 449.14 million shares outstanding. The number of shares has increased by 14.38% in one year.
| Current Share Class | 449.14M |
| Shares Outstanding | 449.14M |
| Shares Change (YoY) | +14.38% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.21% |
| Owned by Institutions (%) | 77.37% |
| Float | 410.57M |
Valuation Ratios
The trailing PE ratio is 11.65.
| PE Ratio | 11.65 |
| Forward PE | n/a |
| PS Ratio | 10.29 |
| PB Ratio | 1.24 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 10.09 |
| EV / Sales | 8.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.22, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.22 |
| Quick Ratio | 2.59 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -64.33 |
Financial Efficiency
Return on equity (ROE) is -37.88% and return on invested capital (ROIC) is -44.73%.
| Return on Equity (ROE) | -37.88% |
| Return on Assets (ROA) | -19.44% |
| Return on Invested Capital (ROIC) | -44.73% |
| Return on Capital Employed (ROCE) | -37.26% |
| Weighted Average Cost of Capital (WACC) | 9.06% |
| Revenue Per Employee | 57,692 |
| Profits Per Employee | 50,962 |
| Employee Count | 129 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.38 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.91 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 12.67 |
| 200-Day Moving Average | 12.33 |
| Relative Strength Index (RSI) | 56.87 |
| Average Volume (20 Days) | 931,886 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AIM:CREO had revenue of GBP 6.00 million and earned 5.30 million in profits. Earnings per share was 0.01.
| Revenue | 6.00M |
| Gross Profit | 2.40M |
| Operating Income | -19.30M |
| Pretax Income | -17.50M |
| Net Income | 5.30M |
| EBITDA | -18.60M |
| EBIT | -19.30M |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 12.40 million in cash and 4.10 million in debt, with a net cash position of 8.30 million or 0.02 per share.
| Cash & Cash Equivalents | 12.40M |
| Total Debt | 4.10M |
| Net Cash | 8.30M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 50.00M |
| Book Value Per Share | 0.12 |
| Working Capital | 16.20M |
Cash Flow
| Operating Cash Flow | -19.10M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 700,000 |
| Net Borrowing | -600,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 40.00%, with operating and profit margins of -321.67% and 88.33%.
| Gross Margin | 40.00% |
| Operating Margin | -321.67% |
| Pretax Margin | -291.67% |
| Profit Margin | 88.33% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM:CREO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.38% |
| Shareholder Yield | -14.38% |
| Earnings Yield | 8.58% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for AIM:CREO is 50.00, which is 263.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 50.00 |
| Price Target Difference | 263.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 64.89% |
| EPS Growth Forecast (3Y) | -26.87% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AIM:CREO has an Altman Z-Score of -1.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.15 |
| Piotroski F-Score | 3 |